Browse PIK3CB

Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Interaction with PIK3R2 is required for nuclear localization and export.
Domain PF00454 Phosphatidylinositol 3- and 4-kinase
PF00792 Phosphoinositide 3-kinase C2
PF02192 PI3-kinase family
PF00794 PI3-kinase family
PF00613 Phosphoinositide 3-kinase family
Function

Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0001525 angiogenesis
GO:0001935 endothelial cell proliferation
GO:0001952 regulation of cell-matrix adhesion
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006898 receptor-mediated endocytosis
GO:0006909 phagocytosis
GO:0006914 autophagy
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007160 cell-matrix adhesion
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008654 phospholipid biosynthetic process
GO:0010506 regulation of autophagy
GO:0010508 positive regulation of autophagy
GO:0010810 regulation of cell-substrate adhesion
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0030100 regulation of endocytosis
GO:0030168 platelet activation
GO:0030258 lipid modification
GO:0031589 cell-substrate adhesion
GO:0032147 activation of protein kinase activity
GO:0033674 positive regulation of kinase activity
GO:0034109 homotypic cell-cell adhesion
GO:0036092 phosphatidylinositol-3-phosphate biosynthetic process
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis
GO:0040016 embryonic cleavage
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0045017 glycerolipid biosynthetic process
GO:0045860 positive regulation of protein kinase activity
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048514 blood vessel morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050817 coagulation
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0055074 calcium ion homeostasis
GO:0060055 angiogenesis involved in wound healing
GO:0060627 regulation of vesicle-mediated transport
GO:0070527 platelet aggregation
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072583 clathrin-dependent endocytosis
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:2000369 regulation of clathrin-dependent endocytosis
Molecular Function GO:0016303 1-phosphatidylinositol-3-kinase activity
GO:0016307 phosphatidylinositol phosphate kinase activity
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0035005 1-phosphatidylinositol-4-phosphate 3-kinase activity
GO:0043560 insulin receptor substrate binding
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0052742 phosphatidylinositol kinase activity
GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component GO:0005942 phosphatidylinositol 3-kinase complex
GO:0019898 extrinsic component of membrane
GO:0045171 intercellular bridge
GO:0061695 transferase complex, transferring phosphorus-containing groups
> KEGG and Reactome Pathway
 
KEGG hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04024 cAMP signaling pathway
hsa04062 Chemokine signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04068 FoxO signaling pathway
hsa04070 Phosphatidylinositol signaling system
hsa04071 Sphingolipid signaling pathway
hsa04140 Regulation of autophagy
hsa04150 mTOR signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04210 Apoptosis
hsa04360 Axon guidance
hsa04370 VEGF signaling pathway
hsa04380 Osteoclast differentiation
hsa04510 Focal adhesion
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04611 Platelet activation
hsa04620 Toll-like receptor signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
hsa04666 Fc gamma R-mediated phagocytosis
hsa04668 TNF signaling pathway
hsa04670 Leukocyte transendothelial migration
hsa04722 Neurotrophin signaling pathway
hsa04725 Cholinergic synapse
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04810 Regulation of actin cytoskeleton
hsa04910 Insulin signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
hsa04915 Estrogen signaling pathway
hsa04917 Prolactin signaling pathway
hsa04919 Thyroid hormone signaling pathway
hsa04960 Aldosterone-regulated sodium reabsorption
hsa04973 Carbohydrate digestion and absorption
hsa00562 Inositol phosphate metabolism
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1500931: Cell-Cell communication
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-202424: Downstream TCR signaling
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-392451: G beta
R-HSA-397795: G-protein beta
R-HSA-180292: GAB1 signalosome
R-HSA-388396: GPCR downstream signaling
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-373753: Nephrin interactions
R-HSA-1483255: PI Metabolism
R-HSA-109704: PI3K Cascade
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-1483257: Phospholipid metabolism
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-8853659: RET signaling
R-HSA-912631: Regulation of signaling by CBL
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-2029485: Role of phospholipids in phagocytosis
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-1660499: Synthesis of PIPs at the plasma membrane
R-HSA-202403: TCR signaling
R-HSA-210993: Tie2 Signaling
R-HSA-4420097: VEGFA-VEGFR2 Pathway
Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PIK3CB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PIK3CB and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26645196MelanomaResistant to immunotherapyTreatment with a selective PI3Kβ inhibitor improved the efficacy of both anti-PD-1 and anti-CTLA-4 antibodies in murine models.
Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PIK3CB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PIK3CB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6290.0234
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9610.516
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3920.698
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1140.689
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.090.962
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1420.953
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0020.996
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4220.8
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5150.787
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2510.871
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.80.72
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0080.915
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PIK3CB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PIK3CB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PIK3CB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PIK3CB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PIK3CB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PIK3CB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PIK3CB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPIK3CB
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Aliases PIK3C1; phosphoinositide-3-kinase, catalytic, beta polypeptide; P110BETA; PI3KBETA; PI3-kinase p110 subunit ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PIK3CB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PIK3CB.
ID Name Drug Type Targets #Targets
DB00201CaffeineSmall MoleculeADORA1, ADORA2A, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, ......33
DB05241XL765Small MoleculeMTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG5